<DOC>
	<DOCNO>NCT02320487</DOCNO>
	<brief_summary>This Phase 2 , open-label , multicenter study evaluate safety efficacy BG induction therapy participant previously untreated CLL . The anticipated time study treatment 24 week .</brief_summary>
	<brief_title>A Study Obinutuzumab + Bendamustine ( BG ) Participants With Previously Untreated Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Participants must satisfy one criterion treatment initiation , outline iwCLL NCIWG guideline . The criterion include : ( ) Evidence progressive marrow failure manifest development , worsen , anemia and/or thrombocytopenia , ( b ) Massive ( i.e. , great equal [ &gt; = ] 6 centimeter [ cm ] leave costal margin ) progressive symptomatic splenomegaly , ( c ) Massive node ( i.e. , &gt; = 10 cm long diameter ) progressive symptomatic lymphadenopathy , ( ) Progressive lymphocytosis increase great ( &gt; ) 50 percent ( % ) 2month period lymphocyte double time ( LDT ) less ( &lt; ) 6 month , ( e ) Autoimmune anemia and/or thrombocytopenia poorly responsive corticosteroid standard therapy , ( f ) Constitutional symptom , define one follow diseaserelated symptom sign : unintentional weight loss &gt; =10 % within previous 6 month , significant fatigue ( i.e. , Eastern Cooperative Oncology Group Performance Status [ ECOG PS ] 2 bad inability work perform usual activity ) , fevers high 100.5 degree Fahrenheit ( °F ) /38.0 degree Celsius ( °C ) &gt; = 2 week without evidence infection , night sweat &gt; 1 month without evidence infection Absolute neutrophil count ( ANC ) &gt; =1.5 × 10^9 per liter ( /L ) platelets &gt; =75 × 10^9/L unless cytopenia cause underlying disease , i.e. , evidence additional bone marrow dysfunction ( e.g. , myelodysplastic syndrome , hypoplastic bone marrow ) Life expectancy &gt; 6 month ECOG PS 0 , 1 , 2 Willing use acceptable contraceptive measure define protocol least 6 month ( male participant ) 12 month ( female participant ) last dose study drug Pregnant lactating , intend become pregnant study : Women postmenopausal ( &gt; =12 month nontherapyinduced amenorrhea ) surgically sterile must negative serum pregnancy test result within 14 day prior initiation study drug Participants receive previous CLL therapy , include investigational therapy Transformation CLL aggressive nonHodgkin 's lymphoma ( Richter 's transformation ) Inadequate renal function Inadequate liver function : National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Grade 3 liver function test ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] &gt; 5× upper limit normal [ ULN ] &gt; 2 week ; bilirubin &gt; 3× ULN ) unless due underlying disease History malignancy , could affect compliance protocol interpretation result Participants active bacterial , viral , fungal infection require systemic treatment Participants know infection human immunodeficiency virus ( HIV ) human Tcell leukemia virus 1 ( HTLV1 ) Positive hepatitis serology : ( ) Participants positive serology hepatitis B , define positivity hepatitis B surface antigen ( HBsAg ) , participant HBsAg negative hepatitis B core antibody ( antiHBc ) positive , ( b ) Participants positive antiHBc , negative hepatitis B Virus ( HBV ) deoxyribonucleic acid ( DNA ) , consider inclusion Medical Monitor casebycase basis order ensure feasibility monthly DNA test availability appropriate care case hepatitis B reactivation , ( c ) Participants positive serology hepatitis C ( HCV ) unless HCV ( ribonucleic acid [ RNA ] ) confirm negative History severe allergic anaphylactic reaction monoclonal antibody Evidence significant , uncontrolled concomitant disease could affect compliance protocol interpretation result , include significant cardiovascular disease ( New York Heart Association Class III IV cardiac disease , myocardial infarction within previous 6 month , unstable arrhythmia , unstable angina ) pulmonary disease ( include obstructive pulmonary disease history symptomatic bronchospasm ) Vaccination live vaccine minimum 30 day prior study treatment Use investigational agent kind within 30 day study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>